Effectiveness of traditional Chinese medicine transdermal therapy in preventing lower limb deep vein thrombosis in chronic glomerulonephritis and uremic patients

The aim of this study was to assess the impact of traditional Chinese medicine-based transdermal treatment for the prevention of deep vein thrombosis of the lower limbs in patients with chronic glomerulonephritis and uremia. 100 patients hospitalized from January 2022 to July 2024 were randomly divided into a control group (n=50), which was given routine treatment and a study group (n=50), which was given TCM transdermal treatment in addition to herbal formulations at certain acupoints. The treatment was conducted for a period of one month. Clinical endpoints evaluated were the occurrence of deep venous thrombosis (DVT), lower limb pain, Homans sign, femoral triangle tenderness, limb circumference, femoral venous blood flow and coagulation function in terms of prothrombin time (PT), activated partial thromboplastin time (APTT), platelet count (PLT), fibrinogen (FIB) and D-dimer (D-D). The study group presented with significantly lower incidence of DVT, improved venous blood flow and reduced limb swelling and pain compared to the control group (P<0.05). PT and APTT were significantly longer and PLT, FIB and D-D levels were decreased (P<0.05). No severe adverse events were observed and treatment compliance was improved in the study group. These findings suggest that TCM-guided transdermal therapy is a safe and effective adjunctive method for reducing DVT risk in CGN uremia patients.